Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN) secures a US$30m Cresemba milestone payment
Published by Arron Aatkar, PhD

Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, Basilea’s lead antifungal therapy) has triggered a US$30m milestone payment from Pfizer, its license partner in Europe.

Cresemba is marketed in over 70 countries, including the US, most EU member states and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba amounted to US$652m in the 12 months between July 2024 and June 2025, representing  27% growth year-on-year.

Latest

Healthcare | Comment

Immix (NASDAQ: IMMX) to present NEXICART-2 update at ASH 2025

Consumer | Comment

Aston Martin posts £112m Q3 loss

Financials | Comment

Barclays (LON:BARC) Q3 results show momentum